Iodine Quantification to Distinguish Clear Cell from Papillary Renal Cell Carcinoma at Dual-Energy Multidetector CT: A Multireader Diagnostic Performance Study

Mileto, Achille; Marin, Daniele; Alfaro-Cordoba, Marcela; Ramírez-Giraldo, Juan Carlos; Eusemann, Christian D.; Scribano, Emanuele; Blandino, Alfredo; Mazziotti, Silvio; Ascenti, Giorgio

doi:10.1148/radiol.14140171

Cited by 154 publications

(63 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Besides these characteristics observed in our sample, several elaborate imaging-based methods were previously suggested for preoperative pRCC verification. Mileto et al [16] defined a tumour iodine concentration of 0.9 mg/ml as the optimal threshold for discrimination between clear cell and pRCC on CT imaging. Sevcenco et al [17] also noted that diffusion-weighted imaging seems to help distinguish between papillary and other subtypes of RCCs, especially in small renal masses.…”

Section: Discussionmentioning

confidence: 99%

Morphological Characterization of Papillary Renal Cell Carcinoma Type 1, the Efficiency of Its Surgical Treatment

Procházková¹,

Staehler²,

Trávníček³

et al. 2016

Urol Int

View full text Add to dashboard Cite

Aim: Papillary renal cell carcinoma type 1 (pRCC1) represents the second most common type of malignant renal epithelial tumour. The origin of its characteristic appearance, its growth mechanism, and the long-term efficiency of its surgical treatment remain uncertain. Our aim was to determine typical characteristics of surgically treated pRCC1. Methods: pRCC1 was verified in 83 of 1,629 (5.1%) kidney tumours surgically treated in the period of January 2007-January 2016. The clinical and radiological characteristics, type of surgery, histopathology results and follow up data were recorded. Spearman correlation, Kruskal-Wallis analysis of variance, Fisher's exact, and chi-square test were used to analyse appropriate variables. The overall survival rate was evaluated using the Gehan-Wilcoxon test and the Cox proportional hazards model. Results: The mean tumour size was 52.0 mm (15-180); 98.8% of the tumours showed a spherical shape and in 82.1%, exophytic growth was observed. Partial nephrectomy was performed in 80.7%. A majority (81.9%) were classified as pT1. Tumours, 89.2% of them, belonged to Fuhrman grade 1 or 2. The mean follow-up was 46.8 months. The overall survival was associated with pT category (p ≤ 0.0001). Conclusions: Typical signs of pRCC1 are a spherical shape, exophytic growth and low Fuhrman's grade. More than three-fourths of pRCC1 could be treated by the nephron-sparing surgery.

show abstract

Section: Discussionmentioning

confidence: 99%

Morphological Characterization of Papillary Renal Cell Carcinoma Type 1, the Efficiency of Its Surgical Treatment

Procházková¹,

Staehler²,

Trávníček³

et al. 2016

Urol Int

View full text Add to dashboard Cite

show abstract

“…Bis zu ein Drittel der papillären RCC nehmen kein Kontrastmittel auf, so dass eine Unterscheidung zu proteinreichen Zysten schwierigseinkann [9]. Eine Jod-Quantifizierung mittels Dual-Energy-CT wurde als mögliche Methode beschrieben, mit welcher sowohl zwischen dem papillären und klarzelligen RCC als auch zwischen den unterschiedlichen Graden dieser Tumoren differenziert werden könnte, wobei jeweils klarzellige und höhergradige RCC höhere Jod-Konzentrationen aufwiesen [27].…”

Section: Papilläres Rccunclassified

Nichtinvasive Phänotypisierung von Nierentumoren – aktueller Stand

Bickel

2018

Radiologe

View full text Add to dashboard Cite

“…The interaction of these two x-ray beams with body tissues can help in material identification and quantification [18]. These two CT datasets at a low or high polychromatic peak tube energy (kilovoltage, or kV) provide material-specific information that allows for additional characterization of the kidneys and urinary tract [20]. The two varying energy levels can enhance or mute the conspicuity of IV contrast.…”

Section: Renal Cell Carcinomamentioning

confidence: 99%

Advances in medical imaging for the diagnosis and management of common genitourinary cancers

Bagheri

Ahlman

Lindenberg

et al. 2017

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

Medical imaging of the three most common genitourinary (GU) cancers—prostate adenocarcinoma, clear cell renal cell carcinoma (RCC), and urothelial carcinoma of the bladder—has evolved significantly during the past decades. The most commonly used imaging modalities for the diagnosis, staging, and follow-up of GU cancers are computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET). Multiplanar multidetector CT and multiparametric MRI (mpMRI) with diffusion-weighted imaging are the main imaging modalities for RCC and urothelial carcinoma, and while mpMRI is rapidly becoming the main imaging tool in the evaluation of prostate adenocarcinoma, biopsy is still required for diagnosis. Functional and molecular imaging using 18-fluorodeoxyglucose (FDG)-PET, and sodium fluoride (NaF)-PET are essential for the diagnosis, and especially follow-up, of metastatic GU tumors. This review will provide an overview of the latest advances in the imaging of these three major GU cancers.

show abstract

Iodine Quantification to Distinguish Clear Cell from Papillary Renal Cell Carcinoma at Dual-Energy Multidetector CT: A Multireader Diagnostic Performance Study

Abstract: Dual-energy multidetector CT with iodine quantification can be used to distinguish between clear cell and papillary RCC renal cell carcinoma , and it provides insights regarding the tumor grade.

Cited by 154 publications

References 34 publications

Morphological Characterization of Papillary Renal Cell Carcinoma Type 1, the Efficiency of Its Surgical Treatment

Morphological Characterization of Papillary Renal Cell Carcinoma Type 1, the Efficiency of Its Surgical Treatment

Nichtinvasive Phänotypisierung von Nierentumoren – aktueller Stand

Advances in medical imaging for the diagnosis and management of common genitourinary cancers

Contact Info

Product

Resources

About